1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Bactiguard Holding AB (publ)

Bactiguard Holding AB (publ)

BACTI-B.ST
Bactiguard Holding AB (publ)SE flagStockholm Stock Exchange
16.15
SEK
+0.15
- -
565.96MMarket Cap
Bactiguard Holding AB (publ)
BACTI-B.ST
(Stockholm Stock Exchange)

Recent

price

16.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
11,751.6
438.2
12,900.5
12,673.3
3.74
3.95
3.57
4.43
4.51
5.55
5.14
4.84
6.47
5.82
6.9
6.16
6.78
Revenue per Share
-2,475
-2,002
-3,835.9
-340.7
-4.43
-0.8
-0.81
-0.1
-0.45
0.49
-1.14
-1.68
-1.51
-3.95
-0.85
-0.22
-0.53
Basic EPS, GAAP
4,839.6
-1,547.4
-6,111.8
-5,415.1
-2.15
-0.97
-0.6
-0.86
-0.15
1.49
-0.44
- -
-0.22
-1.74
0.29
-0.21
0.21
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2,463.9
18,315.3
-5,812
-12,179.8
-9.28
-7.77
-8.57
-8.67
-9.15
-8.66
-9.74
-11
-12.51
-16.45
-17.31
-17.53
-17.67
Book Value per Share
29,260.8
-44,195.1
-46,075.9
-50,242.9
-4.66
-3.64
-3.83
-3.22
-3.04
-1.82
-2.4
3.28
2.83
-0.1
-0.11
0.4
-0.15
Tangible Book Value per Share
- -
- -
- -
- -
25
33
33
33
33
33
34
35
35
35
35
35
35
Basic Weighted Avg Shares
118
4
129
127
94
131
119
147
150
185
172
169
227
204
242
216
238
Sales/Revenue/Turnover
-31.73
-164.49
5.72
7.22
-41.22
-12.41
-18.86
-0.4
-11.81
9.61
-11.28
-32.05
-23.92
-67.26
-15.81
-3.49
-6.33
Operating Margin (%)
97
2
28
29
30
33
33
35
34
42
44
47
49
40
47
47
44
Depreciation Expense
-25
-20
-38
-3
-111
-27
-27
-3
-15
16
-38
-59
-53
-138
-30
-8
-18
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-21.06
-456.87
-29.73
-2.69
-118.4
-20.17
-22.61
-2.2
-9.95
8.79
-22.28
-34.68
-23.32
-67.84
-12.34
-3.63
-7.76
Profit Margin (%)
-95
62
28
-51
76
-124
-72
37
30
-72
76
258
224
-63
-87
50
33
Working Capital
152
450
461
428
196
- -
50
155
142
72
254
238
228
42
41
149
155
LT Debt
293
183
145
81
443
417
390
387
371
387
373
541
496
353
328
315
309
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
187
14
14
LT Borrowings
- -
119
120
LT Finance Leases
41
38
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
1,237
1,044
995

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
194
130
124
Cash, Cash Equivalents & STI
117
47
46
Accounts Receivable, Net
25
35
28
Inventories
26
21
28
Total Current Liabilities
282
96
92
Payables & Accruals
- -
- -
- -
ST Debt
187
14
14
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.4%
-0.66%
-4.08%
Free Cash Flow
1,901%
4,066.45%
-170.58%
Net Income, GAAP
-21.97%
10.53%
-73.69%
Sales/Revenue/Turnover
6.26%
5.98%
-10.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
54
57
67
63
242
2025
59
48
63
- -
216
2026
42
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.28
-0.41
-0.13
-0.03
-0.85
2025
-0.13
-0.23
0.36
- -
-0.22
2026
-0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BICO Group AB (publ) (CLLKF)
QT Imaging Holdings, Inc. (QTI)
Sonova Holding AG (0QPY.L)
Surgical Innovations Group plc (SUN.L)
Cell Kinetics Ltd. (CKNTF)
Sunridge International, Inc. (SNDZ)
Business
Bactiguard Holding AB (publ) is a Sweden-based MedTech company that develops and licenses infection prevention technology for medical devices; its core offering is the patented Bactiguard Infection Protection (BIP) coating, an ultra-thin noble metal alloy of gold, palladium and silver that prevents bacterial adhesion and biofilm formation. The company provides this technology across urology, orthopedics, cardiology, neurology and other segments through licensing partnerships with leading MedTech firms including Becton Dickinson for urinary catheters such as Bardex IC and Lubrisil IC, Well Lead Medical for catheters and tubes, and Zimmer Biomet for orthopedic trauma implants; it also markets a wound management portfolio featuring Hydrocyn aqua antimicrobial solutions and gels for wound healing and disinfection, alongside sutures including non-absorbable, natural absorbable, synthetic absorbable and specialty types, as well as other wound care products distributed locally. Founded in 2005 and headquartered in Stockholm, Sweden, Bactiguard operates globally with products and licensed solutions available in multiple countries through its partners and distributors. In recent developments, the company reported continued EBITDA profitability in its third quarter 2025 interim results with SEK 5.3 million, despite a 34.5% revenue decline to SEK 48.4 million due to currency effects and prior-year highs, alongside growth in Hydrocyn aqua offsetting suture declines; it completed a strategic transformation in 2024 with updated financial targets emphasizing license business growth and profitability, new leadership under CEO Christine Lind, and strengthened clinical evidence for future expansion.